Before the financial crisis, Tangs was one of the leading biopharmaceutical groups in China, holding a number of scientific research patents in this field.

With the acceleration of globalization, more and more foreign companies are pouring into the domestic market. At first, the influx of these foreign companies only squeezed the living space of some small and medium-sized enterprises in China.

But as these foreign companies take root and mature in China, their existence gradually threatens large family businesses like the Tang Group.

Although the Tang Group is second to none in China, it is not the top in the world. Whether it is financial, material, human or scientific and technological, it is far inferior to the world's top multinational companies.

The development of Tang's Group has gradually been affected, because some cutting-edge scientific and technological problems have not yet been broken, and the cost of the drugs produced by Tang's is very high, so the market sales price is correspondingly higher.

In the process of market competition, price is often the decisive factor.

Some foreign companies have already broken through the technical problems that the Tang Group has not yet broken through, so their production costs are far lower than those of the Tang Group, so they occupy an absolute advantage in the market sales price.

Tang Group attaches great importance to scientific research and innovation, and invests more than 50% of the group's net profits in innovation and research every year.

However, because of the disadvantage in the market competition, Tang's turnover decreased month by month. To add insult to injury, the scientific research of one of Tang's core technologies is in the decisive stage of breakthroughs.

This stage is the most important stage in the research process, and it is also the most expensive and energy-consuming stage.

If sufficient financial support is not guaranteed at this stage, then Tang's years of research are likely to fall short.

Four months ago, under heavy pressure from other directors of the group, Tang Tianou resolutely made the decision to borrow money to support scientific research consumption.

However, the progress of scientific research has not been as planned. By the time expected, the final results were still not obtained.

On the one hand, there are far-off scientific research results, and on the other hand, there are huge loans that are being urged day by day. In the gap between the two, Tang's enterprise finally found it difficult to continue to maintain and declared bankruptcy.

And Tang Tianou was also burdened with a huge arrears of hundreds of millions of yuan, and almost collapsed.

Tang's father calmly stated the current situation, and Tang's mother and Gu Qingcheng sat quietly on the sofa and listened to his story.

When borrowing, Tang's father used the entire Tang Group as collateral and borrowed 200 million from the bank.

Now, Tang's father is unable to repay the loan, so the Tang Group, which is used as collateral, will be owned by the bank.

A month later, the bank will put the Tang Group up in public auction to pay off the debts owed.

At that point, the Tang Group will completely change hands, and thousands of its employees will also be at risk for their careers.

"Old Tang," Tang's mother held her husband's hand tightly and looked at him firmly, "I will face everything with you, even if I lose everything, I can still start over." ”

Tang's mother is an excellent surgeon, who has performed thousands of surgeries and saved thousands of lives in her nearly 20 years of work.

Once, no matter how difficult the illness and bloody scene she faced, her hand holding the scalpel would not tremble in the slightest.

But now, her hands were shaking violently.

After all, the heavy pressure brought about by life changes left a deep shadow in the heart of this strong woman